Showing 3121-3130 of 5773 results for "".
- RxSight Launches LAL+ and Features Multiple Doctor Presentations at ASCRShttps://modernod.com/news/rxsight-announces-commercial-launch-of-the-lal-and-features-multiple-doctor-presentations-at-ascrs/2482213/RxSight announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL and the Light Adjustable Lens+ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small cont
- Zeiss Completes Acquisition of Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-completes-acquisition-of-dutch-ophthalmic-research-center/2482210/Carl Zeiss Meditec announced it has secured all required regulatory approvals and completed the acquisition of Dutch Ophthalmic Research Center (DORC). IN December, Zeiss announced its plans to acquire from the investment firm Eurazeo SE (Paris, France) for about €985 million ($1.0
- Brill Establishes Subsidiary in the United Stateshttps://modernod.com/news/brill-establishes-subsidiary-in-the-united-states/2482209/Brill, the global pharmaceutical company specializing in ophthalmology, announced the establishment of a subsidiary in the United States with headquarters in Miami, Florida, a manufacturing center in Boston, Massachusetts, and strategic locations for distributing healthcare solutions throughout t
- Glaukos Receives Permanent J-Code for iDose TRhttps://modernod.com/news/glaukos-receives-permanent-j-code-for-idose-tr/2482208/Glaukos announced that CMS has assigned a unique, permanent J-code (J7355) for iDose TR (travoprost intracameral implant) 75 mcg, a p
- Aurion Biotech to Present Clinical Data at ASCRShttps://modernod.com/news/aurion-biotech-to-present-clinical-data-at-ascrs/2482204/Aurion Biotech announced several presentations during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held April 5-8, 2024 in Boston. At Eyecelerator and ASCRS, data will be presented from the company’s Escal&
- Centricity Vision to Present at ASCRS and Eyeceleratorhttps://modernod.com/news/centricity-vision-to-present-at-ascrs-and-eyecelerator/2482203/Centricity Vision announced that it will present on its recently launched ZEPTOLink IOL Positioning System during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held April 5-8, 2024 in Boston. Additionally, Leonard Borrmann, the company’s newl
- Nordic Pharma to Present Data on Lacrifill Canaliocular Gel, a Novel Therapy for Dry Eye, at ASCRShttps://modernod.com/news/nordic-pharma-to-present-data-on-lacrifill-canaliocular-gel-a-novel-therapy-for-dry-eye-at-ascrs/2482202/Nordic Pharma will be presenting data on Lacrifill Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Boston, on April 5-8, 2024. Lacrifill Canalicular Gel is a cross-linked hyaluronic acid derivativ
- BioTissue to Present Research Into the Application of Cryopreserved Amniotic Membrane (CAM) at ASCRShttps://modernod.com/news/biotissue-to-present-research-into-the-application-of-cryopreserved-amniotic-membrane-cam-at-ascrs/2482201/Ophthalmologists at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Boston will be sharing research that offers new insights into the application of Cryopreserved Amniotic Membrane (CAM). Among these advancements is the utilization of Bio
- Alcon to Highlight New Data at ASCRS Demonstrating Innovations Designed to Optimize Patient Outcomeshttps://modernod.com/news/alcon-to-highlight-new-data-at-ascrs-demonstrating-innovations-designed-to-optimize-patient-outcomes/2482199/Alcon will showcase approximately 100 company-supported and investigator-led data presentations demonstrating its latest innovative efforts aimed at optimizing patient outcomes at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 5-8, in Boston. In additio
- Melt Pharmaceuticals Completes Stock Refinancing to Support Further Development of MELT-300https://modernod.com/news/melt-pharmaceuticals-completes-stock-refinancing-to-support-further-development-of-melt-300/2482198/Melt Pharmaceuticals announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors. The capital raised will primarily support the further development of MELT-300, including the MELT-300 phase 3 program. MELT-300, a n